• Something wrong with this record ?

Salvage lymphadenectomy after primary therapy with curative intent for prostate cancer

F. Quhal, P. Bryniarski, JG. Rivas, G. Gandaglia, SF. Shariat, P. Rajwa

. 2023 ; 33 (4) : 269-273. [pub] 20230511

Language English Country United States

Document type Review, Journal Article

Persistent link   https://www.medvik.cz/link/bmc23010890

PURPOSE OF REVIEW: To provide a summary of the current literature on salvage lymph node dissection (sLND) in patients with nodal recurrent prostate cancer (PCa) with focus on imaging, the extent of sLND and oncologic outcomes. RECENT FINDINGS: The clinical practice guidelines recommend performing PET/CT in patients with biochemical recurrence (BCR) after primary therapy. PSMA PET/CT has demonstrated superiority over choline PET/CT and MRI, especially at low prostate-specific antigen (PSA) levels. Although the heterogeneity in available literature does not allow standardization of surgical templates for sLND and PET/CT scan can guide the extent of surgical dissection, an anatomically defined extended template is typically considered. Radio-guided surgery (RGS) suggests an improved positive lymph node yield compared with standard sLND. However, long-term data are needed to evaluate the oncologic impact of sLND. The main aims of sLND are to delay recurrence and to postpone the need for systemic therapy. Available evidence suggests that around 40-80% of men can achieve complete biochemical response after sLND and 10-30% remain BCR free after 5 years. Robotic sLND might represent an option to reduce the risk of complications without compromising oncological outcomes; validation in controlled prospective studies is, however, needed. SUMMARY: sLND is a valid treatment option for patients with nodal recurrence only after primary therapy for PCa. Further optimization of patient selection based on highly sensitive and specific imaging and clinical factors remains an unmet need. To maximize the benefit of this approach, sLND should be discussed with patients who harbor lymph node-only recurrence after primary therapy in a shared decision-making.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010890
003      
CZ-PrNML
005      
20230801132657.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MOU.0000000000001103 $2 doi
035    __
$a (PubMed)37166270
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Quhal, Fahad $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
245    10
$a Salvage lymphadenectomy after primary therapy with curative intent for prostate cancer / $c F. Quhal, P. Bryniarski, JG. Rivas, G. Gandaglia, SF. Shariat, P. Rajwa
520    9_
$a PURPOSE OF REVIEW: To provide a summary of the current literature on salvage lymph node dissection (sLND) in patients with nodal recurrent prostate cancer (PCa) with focus on imaging, the extent of sLND and oncologic outcomes. RECENT FINDINGS: The clinical practice guidelines recommend performing PET/CT in patients with biochemical recurrence (BCR) after primary therapy. PSMA PET/CT has demonstrated superiority over choline PET/CT and MRI, especially at low prostate-specific antigen (PSA) levels. Although the heterogeneity in available literature does not allow standardization of surgical templates for sLND and PET/CT scan can guide the extent of surgical dissection, an anatomically defined extended template is typically considered. Radio-guided surgery (RGS) suggests an improved positive lymph node yield compared with standard sLND. However, long-term data are needed to evaluate the oncologic impact of sLND. The main aims of sLND are to delay recurrence and to postpone the need for systemic therapy. Available evidence suggests that around 40-80% of men can achieve complete biochemical response after sLND and 10-30% remain BCR free after 5 years. Robotic sLND might represent an option to reduce the risk of complications without compromising oncological outcomes; validation in controlled prospective studies is, however, needed. SUMMARY: sLND is a valid treatment option for patients with nodal recurrence only after primary therapy for PCa. Further optimization of patient selection based on highly sensitive and specific imaging and clinical factors remains an unmet need. To maximize the benefit of this approach, sLND should be discussed with patients who harbor lymph node-only recurrence after primary therapy in a shared decision-making.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a PET/CT $x metody $7 D000072078
650    _2
$a prospektivní studie $7 D011446
650    _2
$a záchranná terapie $x metody $7 D016879
650    _2
$a lokální recidiva nádoru $x patologie $7 D009364
650    _2
$a lymfadenektomie $x škodlivé účinky $x metody $7 D008197
650    12
$a nádory prostaty $x diagnostické zobrazování $x chirurgie $x patologie $7 D011471
650    _2
$a prostatektomie $7 D011468
655    _2
$a přehledy $7 D016454
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bryniarski, Piotr $u Department of Urology, Medical University of Silesia, Zabrze, Poland
700    1_
$a Rivas, Juan Gomez $u Department of Urology, Hospital Clínico San Carlos, Madrid, Spain
700    1_
$a Gandaglia, Giorgio $u Unit of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, New York, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA $u Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
700    1_
$a Rajwa, Pawel $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Medical University of Silesia, Zabrze, Poland
773    0_
$w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 33, č. 4 (2023), s. 269-273
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37166270 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132654 $b ABA008
999    __
$a ok $b bmc $g 1963354 $s 1197155
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 33 $c 4 $d 269-273 $e 20230511 $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options